Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 04, 2016 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Announces Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

CAMBRIDGE, Mass., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
August 24, 2016 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Announces Participation in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
August 11, 2016 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Reports Recent Corporate Progress and Second Quarter 2016 Financial Results

Ongoing Phase 1/2 trial DTX101 for hemophilia B clinical data expected later this year Lead IMD program, DTX301 for OTC deficiency, progressing toward IND filing Advancing broad inherited...
August 02, 2016 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference

CAMBRIDGE, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
June 29, 2016 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

CAMBRIDGE, Mass., June 29, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
June 22, 2016 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Announces Recombinant DNA Advisory Committee’s Unanimous Approval of Phase 1/2 Study Protocol for DTX301, Lead Inherited Metabolic Disease (IMD) Product Candidate to Treat OTC Deficiency

CAMBRIDGE, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
June 21, 2016 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Opens New Facility in Woburn and Expands Management Team

CAMBRIDGE, Mass., June 21, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
May 31, 2016 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass., May 31, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
May 27, 2016 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Announces Presentations at the 8th European Conference on Rare Diseases & Orphan Products (ECRD)

CAMBRIDGE, Mass., May 27, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
May 19, 2016 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Announces Presentations at the Upcoming 21st Congress of the European Hematology Association (EHA)

CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies...